Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912).

Jennifer H FosterStephan D VossDavid C Hall Charles G MinardFrank M BalisKeith WilnerStacey L BergElizabeth FoxPeter C AdamsonSusan M BlaneyBrenda J WeigelYael P Mosse

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Despite limited activity seen in this trial, we conclude that this is more likely due to an inability to reach the higher concentrations of crizotinib needed to overcome the competing ATP affinity.See related commentary by Schulte and Eggert, p. 3507.

Keyphrases

advanced non small cell lung cancer
acute lymphoblastic leukemia
acute myeloid leukemia
palliative care
clinical trial
young adults
multiple myeloma
phase iii
diffuse large b cell lymphoma
hodgkin lymphoma
epidermal growth factor receptor
mass spectrometry
open label